Full Press Release Details
Announces U.S. Commercial Launch of CGuard Prime Carotid Stent System for the Prevention of Stroke
Florida - July 9, 2025 (GLOBE NEWSWIRE) - InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system
for the prevention of stroke, today announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., following
its premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA).
CGuard Prime was engineered specifically to minimize both early and late embolism risk by effectively trapping potential emboli against
the arterial wall while preserving external carotid artery perfusion. This innovative device features three key advantages: First, a
dual layer design that combines the largest open-cell frame with the smallest mesh pore size available. Second, the MicroNet ,
a bio-stable mesh crafted from a single 20 m Polyethylene Terephthalate (PET) strand that traps and seals thrombus and plaque against
the vessel wall to prevent embolization. Third, SmartFit technology eliminates the need for tapered versions while ensuring precise
vessel wall apposition.
U.S. commercial launch marks a pivotal milestone in InspireMD's expansion history, having already secured double-digit market share
across more than 30 countries," said Marvin Slosman, Chief Executive Officer of InspireMD. "We've spent the past year
meticulously preparing for this moment, assembling a world-class commercial team comprised of industry veterans with deep expertise and
longstanding relationships. Backed by this all-star team and a robust operational infrastructure, we are poised to execute a highly impactful
U.S. launch. We're incredibly grateful to everyone who contributed to making this possible and couldn't be more excited about
patients with the CGuard Prime system is incredibly meaningful, both personally, for the advancement of innovation at OhioHealth, and
for the field of carotid intervention as a whole," said Dr. D. Chris Metzger, System Vascular Chief at OhioHealth. "CGuard's
unique design makes a real difference in addressing the complexities of carotid artery disease, offering enhanced embolic protection
without compromising deliverability. My experience using the system-both in clinical trials and now in practice-reinforces
how much demand there is for safer, less invasive alternatives, particularly for patients at higher risk of stroke. This technology represents
an important advancement in how we approach stroke prevention in the U.S."
team at Ballad Health is thrilled to have contributed to the journey of this novel next generation carotid device. From initiating the
first C-GUARDIANS enrollments in 2021 and leading enrollment throughout the trial to supporting the first commercial case by Dr. Chris
Metzger, we have been a crucial contributor to the full life cycle of this technology to date. Our efforts reflect the commitment of
the Ballad Health System to advancing innovation to improve patient care and offering the latest in medical breakthrough technologies,"
shared Alan Levine, Chairman and CEO, Ballad Health.
CGuard Prime Carotid Stent System is a novel mesh-covered carotid stent designed to improve patient safety through sustained embolic
protection. CGuard Prime combines the largest open-cell frame of available carotid stents with the smallest mesh pore size, preventing
plaque protrusion through the stent, for lasting embolic protection demonstrated beyond five years.
seeks to utilize its proprietary MicroNet mesh technology to make its products the industry standard for carotid stenting by providing
outstanding acute results and durable, stroke-free long-term outcomes. InspireMD's common stock is quoted on Nasdaq under the ticker
routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
press release contains "forward-looking statements." Forward-looking statements include, but are not limited to, statements
regarding InspireMD or its management team's expectations, hopes, beliefs, intentions or strategies regarding future events, future
financial performance, strategies, expectations, competitive environment and regulation, including potential U.S. commercial launch and
expectations regarding the exercise of any warrants. Such statements may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts,"
"estimates," "aims," "believes," "hopes," "potential", "scheduled"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject
to various known and unknown risks and uncertainties, many of which are beyond the company's control, and cannot be predicted or
quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and
negative cash flows from operating activities; substantial doubt about our ability to continue as a going concern; significant future
commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; our need to raise
additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and
could dilute out stockholders' ownership interests; market acceptance of our products; an inability to secure and maintain regulatory
approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain
compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals
for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and
our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data
collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative
to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological,
research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;
entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development
and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product
liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental
and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel
and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency
exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political
and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture
our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions
and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking
statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free
of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or otherwise.